Alexander C Egbe1, Sushil A Luis1, Ratnasari Padang1, Carole A Warnes2. 1. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. 2. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address: warnes.carole@mayo.edu.
Abstract
BACKGROUND: A direct comparison of outcomes between moderate mixed aortic valve disease (MAVD) and isolated aortic stenosis (AS) or aortic regurgitation (AR) has not been performed, making evidence-based recommendations difficult in patients with MAVD. OBJECTIVES: This study sought to determine adverse event (AE) occurrence (the primary endpoint), defined as New York Heart Association functional class III/IV symptoms, aortic valve replacement, or cardiac death, and to compare AE rates between MAVD and isolated AS or AR. METHODS: Asymptomatic patients were identified with moderate MAVD and an ejection fraction ≥50% and were followed at Mayo Clinic from 1994 to 2013. Moderate MAVD was defined as a combination of moderate AS and moderate AR. Age- and sex-matched control groups were selected with isolated moderate AR (n = 117), moderate AS (n = 117), or severe AS (n = 117). RESULTS: At 9.1 ± 4.2 years of follow-up, patients with moderate MAVD (n = 251) had a mean age of 63 ± 11 years, 73% were male, and 38% had bicuspid valve. AE occurred in 193 (77%) patients in this group, including symptom development (69%), aortic valve replacement (67%), and cardiac death (4%). Predictors of AE were older age (hazard ratio [HR]: 1.71 per decade; 95% confidence interval [CI]: 1.38 to 1.97 per decade; p = 0.001), and relative wall thickness >0.42 (HR: 2.01; 95% CI: 1.86 to 2.33; p = 0.002). AE rates were similar in the MAVD and severe AS group (71% vs. 68% at 5 years; p = 0.49), but were significantly higher compared with the moderate AS and AR groups. CONCLUSIONS: MAVD patients had outcomes comparable to those with severe AS, and preserved ejection fraction and should be monitored closely for symptoms.
BACKGROUND: A direct comparison of outcomes between moderate mixed aortic valve disease (MAVD) and isolated aortic stenosis (AS) or aortic regurgitation (AR) has not been performed, making evidence-based recommendations difficult in patients with MAVD. OBJECTIVES: This study sought to determine adverse event (AE) occurrence (the primary endpoint), defined as New York Heart Association functional class III/IV symptoms, aortic valve replacement, or cardiac death, and to compare AE rates between MAVD and isolated AS or AR. METHODS: Asymptomatic patients were identified with moderate MAVD and an ejection fraction ≥50% and were followed at Mayo Clinic from 1994 to 2013. Moderate MAVD was defined as a combination of moderate AS and moderate AR. Age- and sex-matched control groups were selected with isolated moderate AR (n = 117), moderate AS (n = 117), or severe AS (n = 117). RESULTS: At 9.1 ± 4.2 years of follow-up, patients with moderate MAVD (n = 251) had a mean age of 63 ± 11 years, 73% were male, and 38% had bicuspid valve. AE occurred in 193 (77%) patients in this group, including symptom development (69%), aortic valve replacement (67%), and cardiac death (4%). Predictors of AE were older age (hazard ratio [HR]: 1.71 per decade; 95% confidence interval [CI]: 1.38 to 1.97 per decade; p = 0.001), and relative wall thickness >0.42 (HR: 2.01; 95% CI: 1.86 to 2.33; p = 0.002). AE rates were similar in the MAVD and severe AS group (71% vs. 68% at 5 years; p = 0.49), but were significantly higher compared with the moderate AS and AR groups. CONCLUSIONS: MAVD patients had outcomes comparable to those with severe AS, and preserved ejection fraction and should be monitored closely for symptoms.
Authors: Heather A Stefek; Haben Berhane; Joshua D Robinson; Brian Reilly; Alexander Ruh; Michael Markl; Cynthia K Rigsby Journal: Pediatr Cardiol Date: 2019-07-24 Impact factor: 1.655
Authors: Jennifer L Philip; Tiffany Zens; Lucian Lozonschi; Nilto C De Oliveira; Satoru Osaki; Takushi Kohmoto; Shahab A Akhter; Paul C Tang Journal: J Thorac Dis Date: 2018-07 Impact factor: 2.895
Authors: Michelle S Lim; Geoff Strange; David Playford; Simon Stewart; David S Celermajer Journal: J Am Heart Assoc Date: 2021-08-28 Impact factor: 5.501
Authors: Harish Appa; Kenneth Park; Deon Bezuidenhout; Braden van Breda; Bruce de Jongh; Jandré de Villiers; Reno Chacko; Jacques Scherman; Chima Ofoegbu; Justiaan Swanevelder; Michael Cousins; Paul Human; Robin Smith; Ferdinand Vogt; Bruno K Podesser; Christoph Schmitz; Lenard Conradi; Hendrik Treede; Holger Schröfel; Theodor Fischlein; Martin Grabenwöger; Xinjin Luo; Heather Coombes; Simon Matskeplishvili; David F Williams; Peter Zilla Journal: Front Cardiovasc Med Date: 2022-03-03
Authors: Nicolas Isaza; Milind Y Desai; Samir R Kapadia; Amar Krishnaswamy; L Leonardo Rodriguez; Richard A Grimm; Julijana Z Conic; Yoshihito Saijo; Eric E Roselli; A Marc Gillinov; Douglas R Johnston; Lars G Svensson; Brian P Griffin; Zoran B Popović Journal: J Am Heart Assoc Date: 2020-03-24 Impact factor: 5.501